|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Rgmおよびそのモジュレーターの用途
|
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
WO2011027349A1
(en)
|
2009-09-06 |
2011-03-10 |
Protab Ltd. |
Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
|
|
EP2510001B1
(en)
|
2009-12-08 |
2015-12-02 |
AbbVie Deutschland GmbH & Co KG |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
WO2011138392A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
US8766034B2
(en)
|
2010-09-22 |
2014-07-01 |
Cedars-Sinai Medical Center |
TL1A model of inflammation fibrosis and autoimmunity
|
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
US20140050733A1
(en)
|
2011-02-07 |
2014-02-20 |
Dale B. Schenk |
Apoe immunotherapy
|
|
WO2012109624A2
(en)
|
2011-02-11 |
2012-08-16 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
CA2836898A1
(en)
*
|
2011-05-20 |
2012-11-29 |
Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
JP6281163B2
(ja)
|
2011-08-22 |
2018-02-21 |
エメルゲント バイオソリューションズ カナダ |
クロストリジウム・ディフィシレ抗体
|
|
KR101982899B1
(ko)
*
|
2011-09-30 |
2019-05-27 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
TL1a에 대한 항체 및 그의 용도
|
|
WO2013067355A1
(en)
|
2011-11-04 |
2013-05-10 |
Novartis Ag |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗mcam抗體及相關使用方法
|
|
WO2014055967A2
(en)
*
|
2012-10-05 |
2014-04-10 |
Neotope Biosciences Limited |
Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
|
|
EA201591153A1
(ru)
*
|
2013-01-02 |
2016-01-29 |
Гленмарк Фармасьютикалс С.А. |
Антитела, связывающиеся с tl1a, и их применение
|
|
CU24446B1
(es)
|
2013-03-13 |
2019-10-04 |
Prothena Biosciences Ltd |
Un anticuerpo monoclonal humanizado que se une a tau
|
|
CA2908553A1
(en)
*
|
2013-03-27 |
2014-10-02 |
Cedars-Sinai Medical Center |
Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
|
|
KR102042174B1
(ko)
|
2013-03-29 |
2019-11-08 |
삼성전자주식회사 |
인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도
|
|
EP4105236A1
(en)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
|
|
TWI777196B
(zh)
*
|
2013-08-05 |
2022-09-11 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(五)
|
|
US20160264684A1
(en)
*
|
2013-10-10 |
2016-09-15 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
BR112016009797A2
(pt)
*
|
2013-11-13 |
2017-12-05 |
Bristol Myers Squibb Co |
anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
|
|
DK3116911T3
(da)
|
2014-03-12 |
2019-09-30 |
Prothena Biosciences Ltd |
Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
|
|
WO2015136472A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg4-5
|
|
US10160805B2
(en)
|
2014-07-11 |
2018-12-25 |
New York University |
Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
EP3218005B1
(en)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
ES2795818T3
(es)
*
|
2015-03-18 |
2020-11-24 |
Seattle Genetics Inc |
Anticuerpos CD48 y conjugados de los mismos
|
|
US20170021020A1
(en)
|
2015-07-23 |
2017-01-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibody and vaccine targeting filamentous bacteriophage
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
CN108289953B
(zh)
|
2015-09-29 |
2022-03-11 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
US20180319889A1
(en)
*
|
2015-11-02 |
2018-11-08 |
La Jolla Institute For Allergy & Immunology |
Method and medicament for treating airway and/or lung diseases
|
|
JP7066613B2
(ja)
|
2015-11-12 |
2022-05-13 |
シージェン インコーポレイテッド |
グリカン相互作用化合物および使用方法
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
JP7082945B2
(ja)
|
2016-03-17 |
2022-06-09 |
シーダーズ―シナイ メディカル センター |
Rnaset2により炎症性腸疾患を診断する方法
|
|
EP3436480A4
(en)
*
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
|
BR112018072394A2
(pt)
|
2016-05-02 |
2019-02-19 |
Prothena Biosciences Limited |
anticorpos que reconhecem a tau
|
|
ES2933491T3
(es)
|
2016-05-02 |
2023-02-09 |
Prothena Biosciences Ltd |
Inmunoterapia tau
|
|
US10889638B2
(en)
|
2016-05-02 |
2021-01-12 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EP3455256A1
(en)
*
|
2016-05-09 |
2019-03-20 |
Bristol-Myers Squibb Company |
Tl1a antibodies and uses thereof
|
|
CN109476698B
(zh)
|
2016-05-20 |
2023-10-17 |
西达-赛奈医疗中心 |
基于基因的炎性肠病诊断
|
|
RU2630647C1
(ru)
*
|
2016-05-27 |
2017-09-11 |
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства |
ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
|
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
|
EA201990747A1
(ru)
*
|
2016-09-19 |
2019-10-31 |
|
Способы лечения иммунных нарушений с применением белков, связывающих pd–1
|
|
MY191324A
(en)
*
|
2016-10-26 |
2022-06-15 |
Cedars Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
JP7303182B2
(ja)
*
|
2017-04-21 |
2023-07-04 |
メリタス エルエルシー |
糖尿病関連用途のための方法及び抗体
|
|
US11958896B2
(en)
|
2017-05-02 |
2024-04-16 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CA3098374A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Prometheus Biosciences, Inc. |
Optimized anti-tl1a antibodies
|
|
RU2687609C1
(ru)
*
|
2018-05-30 |
2019-05-15 |
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства |
Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CA3127113A1
(en)
|
2019-01-30 |
2020-08-06 |
Dongxu Sun |
Anti-gal3 antibodies and uses thereof
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
PE20212324A1
(es)
|
2019-03-03 |
2021-12-14 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
|
CA3158638A1
(en)
|
2019-10-24 |
2021-04-29 |
Prometheus Biosciences, Inc. |
Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
JP2023510866A
(ja)
*
|
2020-01-13 |
2023-03-15 |
トゥルーバインディング,インコーポレイテッド |
抗gal3抗体および使用方法
|
|
US20230192824A1
(en)
*
|
2020-04-02 |
2023-06-22 |
United States Of America As Represented By The Secretary Of The Navy |
Antigen Binding Proteins to Class 5 ETEC Adhesins
|
|
JP2023528797A
(ja)
|
2020-05-26 |
2023-07-06 |
トゥルーバインディング,インコーポレイテッド |
ガレクチン-3を遮断することにより炎症性疾患を処置する方法
|
|
WO2023141297A2
(en)
*
|
2022-01-21 |
2023-07-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereof
|
|
WO2024239006A1
(en)
|
2023-05-17 |
2024-11-21 |
Genentech, Inc. |
Anti-tl1a antibody therapeutic methods
|
|
CN120399074B
(zh)
*
|
2023-06-02 |
2025-12-30 |
安徽金百奥生物科技有限公司 |
一种与人dr3胞外域高亲和力的纳米抗体
|
|
WO2025038473A1
(en)
|
2023-08-11 |
2025-02-20 |
Paragon Therapeutics, Inc. |
Tl1a binding antibodies and methods of use
|
|
CN120530139A
(zh)
*
|
2023-12-29 |
2025-08-22 |
成都优洛生物科技有限公司 |
抗tl1a抗体或其抗原结合片段及应用
|
|
CN120424214A
(zh)
*
|
2024-02-05 |
2025-08-05 |
三生国健药业(上海)股份有限公司 |
一种抗tl1a抗体及其制备方法和用途
|
|
WO2025212534A1
(en)
*
|
2024-04-05 |
2025-10-09 |
Board Of Regents, The University Of Texas System |
Monoclonal antibodies neutralizing marburg and ravn virus
|
|
CN119552252B
(zh)
*
|
2025-01-16 |
2025-11-25 |
华润生物医药有限公司 |
抗tl1a抗体及其制备方法和应用
|